Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Decitabine, and Radiation in Relapsed/Refractory Solid Tumors or Lymphoma
NCT03445858Phase 1Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Feb 2018
- Primary completion
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab and decitabine in solid tumor and lymphoma, sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Feasibility of administering Pembrolizumab in combination with Decitabine and hypofractionated index radiation at 57 days. Started Feb 2018; status: completed.
02
Drugs
pembrolizumabdecitabine
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03445858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03445858.